A phase I study of ro7297089, a B-cell maturation antigen (BCMA)-CD16a bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM)

This article has no abstract
Epistemonikos ID: 70f311e009644e3804a50f2076f3f752726f0aad
First added on: Feb 13, 2025